APA (7th ed.) Citation

De Santis, M., Palou Redorta, J., Nishiyama, H., Krawczyński, M., Seyitkuliev, A., Novikov, A., . . . Hunting, J. (2025). Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): Final analysis of a randomised, open-label, phase 3 trial. Lancet, 406(10516), 2221. https://doi.org/10.1016/S0140-6736(25)01897-5

Chicago Style (17th ed.) Citation

De Santis, Maria, et al. "Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 Trial." Lancet 406, no. 10516 (2025): 2221. https://doi.org/10.1016/S0140-6736(25)01897-5.

MLA (9th ed.) Citation

De Santis, Maria, et al. "Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 Trial." Lancet, vol. 406, no. 10516, 2025, p. 2221, https://doi.org/10.1016/S0140-6736(25)01897-5.